A new class of bispecific antibodies to redirect T cells for cancer immunotherapy

作者：Rossi Diane L; Rossi Edmund A; Cardillo Thomas M; Goldenberg David M^*; Chang Chien Hsing

来源：mAbs, 2014, 6(2): 381-391.

DOI：10.4161/mabs/27385

• bispecific antibody
• T-cell redirected therapy
• DOCK-AND-LOCK
• Burkitt lymphoma
• pancreatic cancer

Various constructs of bispecific antibodies (bsAbs) to redirect effector T cells for the targeted killing of tumor cells have shown considerable promise in both preclinical and clinical studies. The single-chain variable fragment (scFv)-based formats, including bispecific T-cell engager (BiTE) and dual-affinity re-targeting (DART), which provide monovalent binding to both CD3 on T cells and to the target antigen on tumor cells, can exhibit rapid blood clearance and neurological toxicity due to their small size (similar to 55 kDa). Herein, we describe the generation, by the modular DOCK-AND-LOCK (TM) (DNL (TM)) method, of novel T-cell redirecting bispecific antibodies, each comprising a monovalent anti-CD3 scFv covalently conjugated to a stabilized dimer of different anti-tumor Fabs. The potential advantages of this design include bivalent binding to tumor cells, a larger size (similar to 130 kDa) to preclude renal clearance and penetration of the blood-brain barrier, and potent T-cell mediated cytotoxicity. These prototypes were purified to near homogeneity, and representative constructs were shown to provoke the formation of immunological synapses between T cells and their target tumor cells in vitro, resulting in T-cell activation and proliferation, as well as potent T-cell mediated anti-tumor activity. In addition, in vivo studies in NOD/SCID mice bearing Raji Burkitt lymphoma or Capan-1 pancreatic carcinoma indicated statistically significant inhibition of tumor growth compared with untreated controls.

• 出版日期2014-4